Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Top Cited Papers
Open Access
- 1 September 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (9), 1156-1164
- https://doi.org/10.1001/archneurol.2011.103
Abstract
ObjectiveTo describe the development of progressive multifocal leukoencephalopathy (PML) in patients with rheumatoid arthritis (RA) treated with rituximab.DesignCase study.SettingClinical care for patients with rheumatologic diseases. Most were referred to academic centers for care after diagnosis (Washington University, St Louis, Missouri; Karolinska Insitute, Stockholm, Sweden; and Royal Melbourne Hospital, Melbourne, Australia) while one was cared for in a neurology practice in Dallas, Texas, with consultation by an academic neurovirologist from the University of Colorado in Denver.PatientsFour patients developing PML in the setting of rituximab therapy for RA.InterventionRituximab therapy.Main Outcome MeasuresClinical and pathological observations.ResultsFour patients from an estimated population of 129 000 exposed to rituximab therapy for RA are reported in whom PML developed after administration of this drug. All were women older than 50 years, commonly with Sjögren syndrome and a history of treatment for joint disease ranging from 3 to 14 years. One case had no prior biologic and minimal immunosuppressive therapy. Progressive multifocal leukoencephalopathy presented as a progressive neurological disorder, with diagnosis confirmed by detection of JC virus DNA in the cerebrospinal fluid or brain biopsy specimen. Two patients died in less than 1 year from PML diagnosis, while 2 remain alive after treatment withdrawal. Magnetic resonance scans and tissue evaluation confirmed the frequent development of inflammatory PML during the course of the disease.ConclusionThese cases suggest an increased risk, about 1 case per 25 000 individuals, of PML in patients with RA being treated with rituximab. Inflammatory PML may occur in this setting even while CD20 counts remain low.Keywords
This publication has 32 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?Annals of Neurology, 2006
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2006
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2005
- Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRINeuroradiology, 2003
- Highly Active Antiretroviral Therapy and Progressive Multifocal Leukoencephalopathy: Effects on Cerebrospinal Fluid Markers of JC Virus Replication and Immune ResponseClinical Infectious Diseases, 2000
- Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 1998
- Progressive Multifocal Leukoencephalopathy in Patients with HIV InfectionJournal of NeuroVirology, 1998
- Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainClinical Microbiology Reviews, 1992